# A Study of Setmelanotide in Patients With Prader-Willi Syndrome

> **NCT06772597** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Rhythm Pharmaceuticals, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Prader-Willi Syndrome
- Obesity
- Hyperphagia

## Interventions

- **DRUG:** Setmelanotide

## Key facts

- **NCT ID:** NCT06772597
- **Lead sponsor:** Rhythm Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-04
- **Primary completion:** 2026-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06772597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06772597, "A Study of Setmelanotide in Patients With Prader-Willi Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06772597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*